Testing capacity increased five-fold to meet growing demands
KING OF PRUSSIA, PA, Oct. 30 /CNW/ - MDS Pharma Services, a leading
provider of innovative drug discovery and development solutions, announced
today a significant expansion of its central lab operations in China. The
contract research organization has moved to a new, larger facility in Beijing
to meet the growing demands from pharmaceutical and biotech companies
conducting clinical trials in China.
With almost 25,000 square feet, the new facility offers a five-time
increase in testing capacity, four times the space to produce clinical trial
kits, and a wider range of specialized clinical trial testing services. This
new facility's proximity to the Beijing airport also facilitates faster
transportation of clinical trial samples.
"We are excited about how this significant expansion will better serve
the growing needs of our clients," said MDS Pharma Services President David
Spaight. "With many pharmaceutical and biotech companies now making China part
of their global clinical trial programs, we recognized the need to expand our
central lab operations and offer more diverse testing options."
This new central lab facility specializes in molecular biology testing
for infectious diseases, DNA banking and pharmacogenomics - the study of genes
to develop therapies tailored to a person's genetic makeup. It also offers
enhanced molecular biology techniques, a microbiology lab and flow cytometry
capabilities - a technology used increasingly in oncology and immune
disorders. MDS Pharma Services continues to offer project and data management
from this new facility.
MDS Pharma Services has been in China for more than 10 years and has
managed more than 30,000 patients in clinical trials. As an industry pioneer,
it introduced standardized clinical research services to China. It was the
first western contract research organization to own its facility in China and
the first clinical laboratory in China to receive accreditation from the
College of American Pathologists. It also maintains the National
Glycohemoglobin Standardization Program Level I certification.
In addition to the Beijing site, MDS Pharma Services offers central
laboratory services in key geographic areas around the world, including
Canada, the United States, France, Germany, Singapore and South America.
About MDS Pharma Services
MDS Pharma Services offers a full spectrum of resources to meet the drug
discovery and development needs of the pharmaceutical and biotechnology
industries. With numerous facilities strategically located around the world,
we apply advanced scientific and technological expertise throughout the drug
discovery and development process - from lead optimization, pre-IND research,
early clinical research (bioequivalence, phases I-IIa) and bioanalysis through
to global clinical development (phases IIb-IV), central lab and centralized
cardiac services. For more information, visit our website at www.mdsps.com.
MDS Pharma Services is a business unit of MDS Inc. (TSX: MDS; NYSE: MDZ),
a global life sciences company that provides market-leading products and
services that our customers need for the development of drugs and diagnosis
and treatment of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging, radiotherapeutics,
and analytical instruments. MDS has more than 6,200 highly skilled people in
28 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222,
24 hours a day.
/NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
the CNW Photo Network and archived at http://photos.newswire.ca.
Additional archived images are also available on the CNW Photo Archive
website at http://photos.newswire.ca. Images are free to accredited
members of the media/
For further information:
For further information: Investors, Sharon Mathers, (416) 675-6777, ext.
34721, firstname.lastname@example.org; Media, Charlene McGrady, (610) 239-7900,
ext. 231, email@example.com